Long term effect of LDL apheresis in Japan. LDL Apheresis Study Group.

Abstract

LDL-apheresis is introduced in many cases all over Japan. Among them, evaluation of long-term effect on ischemic heart disease (IHD) has made on 10 cases with homozygous familial hypercholesterolemia (FH) and 49 cases with heterozygous FH. As to homozygous FH, 3 patients had angina pectoris. Mean duration of treatment was 26 months (52 treatments). The changes in total cholesterol (TC) in each treatment was from 426 mg/dl to 151 mg/dl. Improvement in IHD was observed in 5 out of 10 cases. As to heterozygous FH, 17 cases had history of myocardial infarction and 12 had angina pectoris. Mean duration of treatment was 13 months (19 treatments). Mean TC was decreased from 271 mg/dl to 126 mg/dl by each treatment. Regression in Achilles tendon thickenting or skin and palpebral xanthomas was observed. Frequency of anginal attacks decreased in 8 out of 17 cases. Ischemic change in ECG were improved in 3 out of 26 cases. Coronary angiography performed with 2 to 3 years of interval in some cases revealed regression or no progression in coronary stenosis. As a whole, IHD improved in 15 cases and exacerbated in 2 cases. Main side effect was hypotension attack. Bradycardia and anginal attack during treatment were observed in some cases. LDL-apheresis was judged as effective in 25 out of 44 patients with IHD or xanthoma.

• Authors: C Naito, A Yamamoto, Y Saito, E Muto, T Nishide, M Shinomiya, M Mukai, S Tomono, T Sato, K Yasuda
• Journal: Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology (Biomater Artif Cells Immobilization Biotechnol) Vol. 19 Issue 1 Pg. 19-26 ( 1991) ISSN: 1055-7172 [Print] United States
• PMID: 1751669 (Publication Type: Journal Article)

Chemical References

• Cholesterol, LDL
• Lipids
• Cholesterol

Topics

• Blood Component Removal (adverse effects)
• Cholesterol (blood)
• Cholesterol, LDL (isolation & purification)
• Coronary Disease (blood, therapy)
• Heterozygote
• Homozygote
• Humans
• Hyperlipoproteinemia Type II (genetics, therapy)
• Japan (epidemiology)
• Lipids (blood)
• Time Factors
• Xanthomatosis (therapy)